Karol Kajo

3.8k total citations · 1 hit paper
134 papers, 2.6k citations indexed

About

Karol Kajo is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Karol Kajo has authored 134 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 38 papers in Cancer Research and 36 papers in Oncology. Recurrent topics in Karol Kajo's work include Testicular diseases and treatments (17 papers), Cancer, Lipids, and Metabolism (14 papers) and Sarcoma Diagnosis and Treatment (11 papers). Karol Kajo is often cited by papers focused on Testicular diseases and treatments (17 papers), Cancer, Lipids, and Metabolism (14 papers) and Sarcoma Diagnosis and Treatment (11 papers). Karol Kajo collaborates with scholars based in Slovakia, Czechia and Qatar. Karol Kajo's co-authors include Peter Kubatka, Dietrich Büsselberg, Raghad Khalid AL-Ishaq, Mariam Abotaleb, Pavol Žúbor, Katarína Macháleková, Ján Danko, Marián Adamkov, Bianka Bojková and Desanka Výbohová and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Molecular Sciences.

In The Last Decade

Karol Kajo

129 papers receiving 2.6k citations

Hit Papers

Flavonoids and Their Anti-Diabetic Effects: Cellular Mech... 2019 2026 2021 2023 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Flavonoids and Their Anti-Diabetic Effects: Cellular Mechanisms and Effects to Improve Blood Sugar Levels
    2019 490 citations Peter Kubatka, Karol Kajo et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karol Kajo Slovakia 25 1.0k 499 499 408 326 134 2.6k
Ping Zhao China 28 1.5k 1.4× 465 0.9× 220 0.4× 341 0.8× 340 1.0× 147 2.9k
Shugo Suzuki Japan 32 1.1k 1.1× 342 0.7× 467 0.9× 177 0.4× 196 0.6× 141 2.6k
Jie Shi China 25 937 0.9× 455 0.9× 518 1.0× 472 1.2× 162 0.5× 146 3.6k
Yingqun Zhou China 37 1.4k 1.3× 456 0.9× 615 1.2× 500 1.2× 176 0.5× 92 3.3k
Yueshui Zhao China 33 1.5k 1.5× 715 1.4× 618 1.2× 229 0.6× 133 0.4× 116 3.3k
Nicola Maggiano Italy 32 1.1k 1.1× 305 0.6× 449 0.9× 532 1.3× 163 0.5× 81 3.1k
Chin‐Wen Chi Taiwan 32 1.5k 1.4× 509 1.0× 598 1.2× 207 0.5× 192 0.6× 80 3.0k
Makoto Asamoto Japan 33 1.7k 1.7× 515 1.0× 805 1.6× 250 0.6× 144 0.4× 126 3.3k
Toshiya Kuno Japan 31 826 0.8× 360 0.7× 288 0.6× 202 0.5× 110 0.3× 78 2.1k
Peter Greaves United Kingdom 30 938 0.9× 386 0.8× 376 0.8× 203 0.5× 119 0.4× 78 2.7k

Countries citing papers authored by Karol Kajo

Since Specialization
Citations

This map shows the geographic impact of Karol Kajo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karol Kajo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karol Kajo more than expected).

Fields of papers citing papers by Karol Kajo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karol Kajo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karol Kajo. The network helps show where Karol Kajo may publish in the future.

Co-authorship network of co-authors of Karol Kajo

This figure shows the co-authorship network connecting the top 25 collaborators of Karol Kajo. A scholar is included among the top collaborators of Karol Kajo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karol Kajo. Karol Kajo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kajo, Karol, et al.. (2021). Bilateral testicular germ cell tumors – 50 years experience. Bratislavské lekárske listy/Bratislava medical journal. 122(7). 449–453. 5 indexed citations
2.
Samec, Marek, Alena Líšková, Lenka Koklesová, et al.. (2021). Flavonoids Targeting HIF-1: Implications on Cancer Metabolism. Cancers. 13(1). 130–130. 72 indexed citations
3.
Chovanec, Michal, Zuzana Čierna, Katarína Macháleková, et al.. (2018). βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors. BMC Cancer. 18(1). 1062–1062. 19 indexed citations
4.
Žúbor, Pavol, Karol Kajo, Marian Grendár, et al.. (2017). Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients. Oncology Letters. 14(1). 758–766. 8 indexed citations
5.
Kaľavská, Katarína, Zuzana Čierna, Michal Chovanec, et al.. (2017). Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors. Oncology Letters. 13(4). 2177–2185. 14 indexed citations
6.
Kaľavská, Katarína, Michal Chovanec, Miriam Zaťovičová, et al.. (2016). Prognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients. Oncology Letters. 12(4). 2590–2598. 6 indexed citations
7.
Ondrušová, Martina, et al.. (2015). Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy. International Urology and Nephrology. 47(7). 1143–1147. 6 indexed citations
8.
Ondruš, D, et al.. (2015). Controversies in the Management of Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer. Klinicka onkologie. 28(2). 112–115. 1 indexed citations
9.
10.
Kajo, Karol, et al.. (2013). [Expression of carbonic anhydrase IX in the breast carcinomas].. PubMed. 78(3). 263–8. 1 indexed citations
11.
Smolková, Božena, et al.. (2013). RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients. Translational Oncology. 6(3). 297–IN5. 41 indexed citations
12.
Kubatka, Peter, Karol Kajo, Katarína Adamicová, et al.. (2012). Immunohistochemical and histomorphological analysis of rat mammary tumors after simvastatin treatment. Neoplasma. 59(5). 516–523. 16 indexed citations
13.
Kubatka, Peter, Jozef Škarda, Karol Kajo, et al.. (2012). Preventive effects of fluvastatin in rat mammary carcinogenesis. European Journal of Cancer Prevention. 22(4). 352–357. 13 indexed citations
14.
Kubatka, Peter, Karol Kajo, Martin Péč, et al.. (2011). Rosuvastatin in the chemoprevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats. Acta veterinaria. 61(5-6). 445–460. 6 indexed citations
15.
Kajo, Karol, et al.. (2011). Sarkomatoidný karcinóm močového mechúra s heterológnou osteosarkomatóznou diferenciáciou. 15(2). 120–125.
16.
Bojková, Bianka, Martin Péč, Peter Kubatka, et al.. (2011). Metabolic Effects of Pioglitazone in Chemically-Induced Mammary Carcinogenesis in Rats. Pathology & Oncology Research. 17(4). 887–892. 5 indexed citations
17.
Žúbor, Pavol, et al.. (2008). Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma. European Journal of Cancer Prevention. 17(1). 33–38. 22 indexed citations
18.
Kubatka, Peter, et al.. (2008). Neoplastic effects of exemestane in premenopausal breast cancer model.. PubMed. 55(6). 538–43. 5 indexed citations
19.
Kajo, Karol, et al.. (2007). Scoring index for prediction of HER-2 status in the invasive breast carcinoma.. PubMed. 29(4). 281–6. 3 indexed citations
20.
Kajo, Karol, Lukáš Plank, A. Miroššay, et al.. (2006). Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters.. PubMed. 53(2). 128–35. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ping Zhao Breakdown of academic impact, for papers by Shugo Suzuki Breakdown of academic impact, for papers by Jie Shi Breakdown of academic impact, for papers by Yingqun Zhou Breakdown of academic impact, for papers by Yueshui Zhao Breakdown of academic impact, for papers by Nicola Maggiano Breakdown of academic impact, for papers by Chin‐Wen Chi Breakdown of academic impact, for papers by Makoto Asamoto Breakdown of academic impact, for papers by Toshiya Kuno Breakdown of academic impact, for papers by Peter Greaves
Rankless by CCL
2026